La cadena de opciones muestra datos clave de las opciones de acciones de NewAmsterdam Pharma Co a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para NewAmsterdam Pharma Co..

NewAmsterdam Pharma Co (NASDAQ:NAMS) Bolsa, Cadena de Opciones

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CDNA

CLIK

ENVB

FLYW

HCTI

ICCT

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

NamSys Inc

EKSO

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LYEL

APDN

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 16.06%. Currently, Cigna Group has a market capitalization of $85.84 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $929.38 today based on a price of $316.64 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748648720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cigna Group 15 Years Ago Would Be Worth Today

If you've ever assumed retirement meant having a seven-figure nest egg, you're in good company — and maybe a little stressed.
For years, Americans have treated the $1 million mark as the gold standard for retiring comfortably. Anything less? Cue the panic attacks.
But according to Northwestern Mutual's just-released <a href="https://news.northwesternmutual.com/planning-and-progress-study-2025">2025 Planning &amp; Progress Study</a>, the average American now believes they need $1.26 million tucked away to retire in peace. That's actually down from $1.46 million last year.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Sure, the so-called magic number dropped by $200,000, but don't pop the champagne just yet. According to the same study, most Americans are <a href="https://www.benzinga.com/personal-finance/25/02/43856927/billionaire-blackrock-ceo-larry-fink-says-people-are-saving-too-much-and-not-investing-enough-to-retire-with-dignity">still wildly unprepared</a>. More than half – 51% – say it's somewhat or very likely they'll outlive their savings. Only 16% feel confident that outliving their savings is "very unlikely."&nbsp;&nbsp;
So if your retirement plan is "hope for the best," you're not alone.
The ‘magic number' to retire comfortably may be down this year, but it's still far beyond what many people actually have. And the gap isn't just wide — it's a canyon.&nbsp;
<a href="https://institutional.vanguard.com/insights-and-research/report/how-america-saves.html?cmpgn=IIG:TL:HAS:HAS24:SRCH:PS:XX:TL:GG:Unknown:Phrase:TLEAD:20230615:BD:NONE:NONE:KW:401kGeneral&amp;gclsrc=aw.ds&amp;gad_source=1&amp;gad_campaignid=17413933089&amp;gbraid=0AAAAADyd_RXD2epePnTlHlLRHWErHyW3U">Vanguard's 2024 report</a> puts the average 401(k) balance across all age groups at just $134,128. That's barely a tenth of what Americans say they'll need to retire comfortably.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
And what's behind the drop? Inflation is still top of mind, but it's cooled off—dropping from around 6% in 2023 to <a href="https://www.bls.gov/opub/ted/2025/the-consumer-price-index-rose-3-0-percent-from-january-2024-to-january-2025.htm">about 3% in 2024</a>. That doesn't mean prices are falling; it just means they're not rising quite as fast. Groceries still feel like a splurge and rent still makes you cry, but apparently, that slight dip was enough for Americans to shave down their expectations.
Either way, the new target still feels like a stretch. <a href="https://www.benzinga.com/money/smartasset">One in four Americans has just a single year of income saved</a>. Among Gen X'ers, 52% have saved up to three times their annual income, but&nbsp; 54% don't think they'll be financially ready to retire when the time comes.<a href="https://www.asppa-net.org/news/2025/4/magic-number-for-retirement-drops-with-inflation/">&nbsp;</a>
Which raises a fair question—not from a study or expert, just plain observation: Are Americans adjusting the number because they think they can genuinely live on less, or have they just accepted that $1.26 million sounds more reachable than $1.46 million? Maybe this is optimism. Maybe it's financial fatigue.&nbsp;
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
If you're wondering how anyone hits that $1.26 million target: you either start young or start wealthy. To get there by age 65, a 20-year-old would need to sock away $330 a month at a 7% return. <a href="https://www.benzinga.com/personal-finance/24/08/40295808/youre-40-50-or-60-do-you-know-how-much-you-should-have-saved-for-retirement-by-now">Wait until you're 50? </a>That jumps to a casual $3,958 per month.<a href="https://www.asppa-net.org/news/2025/4/magic-number-for-retirement-drops-with-inflation/">&nbsp;</a>
Yes, the goal dipped—but the struggle to reach it hasn't. Americans may be adjusting expectations, but most still have a long way to go before <a href="https://www.benzinga.com/money/are-you-rich">retirement feels anything close to "comfortable."</a>
Read Next:
<ul class="wp-block-list">
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Can You Guess What Americans Think They Need To Retire Comfortably? Hint: The 'Magic Number' Just Dropped From Last Year

<ul class="wp-block-list">
<li>The U.S. Department of Health and Human Services says that around 57% of Americans will need long-term care at some point</li>
<li>Most households have grossly underestimated the potential cost of that long-term care, and aren't aware that they will have to pay out of pocket for much of it</li>
<li>The total cost of long-term care can be significant, extending beyond $100,000</li>
</ul>
Long-term care costs can be significant, extending well beyond $100,000, but experts tell <a href="https://www.cnbc.com/2025/05/17/why-long-term-care-costs-can-be-a-huge-problem.html">CNBC</a> that most households aren't prepared to handle the expense.
"People don't plan for it in advance," certified financial planner Carolyn McClanahan told the network. "It's a huge problem."
A 2022 <a href="https://www.urban.org/research/publication/long-term-services-and-supports-older-americans">report</a> by the U.S. Department of Health and Human Services and the Urban Institute says that 57% of Americans turning 65 will develop a disability that is serious enough to require long-term care. The average cost of this long-term care is $122,400, the report said.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
On average, families will pay for 37% of the total cost of this long-term care out of pocket, with the rest covered by insurance and public programs.&nbsp;
"It's pretty clear [workers] don't have that amount of savings in retirement, that amount of savings in their checking or savings accounts, and the majority don't have long-term care insurance," Employee Benefit Research Institute strategist Bridget Bearden told CNBC. "So where is the money going to come from?"
Costs for long-term care vary widely, depending on where you live. However, <a href="https://www.carescout.com/cost-of-care">data</a> collected by Genworth and CareScout put the national average for a home health aide at $6,483 per month and $5,900 for a spot in an assisted living facility.&nbsp;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
Still, many people grossly underestimate how much long-term care could potentially cost them. A recent Employee Benefit Research Institute <a href="https://www.ebri.org/health/content/employee-perspectives-on-long-term-care">report</a> found that "a significant proportion of future caregivers had not estimated LTC costs," and those who had expected them to remain under $50,000. Additionally, the report found that 43% of future caregivers expected Medicare to cover the costs of long-term care, and 29% expected Medicaid to foot the bill.
Experts told CNBC that estimates like these are not realistic. Health insurance generally doesn't cover long-term care services, and Medicare only covers select aspects, they say.
McClanahan told CNBC that Medicare typically covers skilled care for up to 100 days, which covers things like rehab or medicine administration, but will not cover the custodial care required for daily activities like bathing and dressing.&nbsp;
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
As for Medicaid, the largest payer of long-term care costs, not everyone will qualify. Most people who are eligible for these benefits come from low-income households. "You basically have to be destitute" for Medicaid to kick in, she said.
"The challenge with long-term care costs is they're unpredictable," McClanahan told CNBC. "You don't always know when you'll get sick and need care."&nbsp;
She advises Gen Xers and Millennials to begin planning for potential long-term care needs now. "When you think through it in advance, it keeps the decisions way more level-headed," she said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

'It's A Huge Problem,' Experts Urge Gen Xers And Millennials To Plan For Long-Term Care

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 5 years by 9.52% on an annualized basis producing an average annual return of 23.37%. Currently, Intuitive Surgical has a market capitalization of $197.97 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 5 years ago, it would be worth $288.38 today based on a price of $552.34 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748647811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 15 years by 38.55% on an annualized basis producing an average annual return of 50.71%. Currently, NVIDIA has a market capitalization of $3.29 trillion. 
Buying $100 In NVDA: If an investor had bought $100 of NVDA stock 15 years ago, it would be worth $44,689.54 today based on a price of $134.77 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748646912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 5 years by 51.3% on an annualized basis producing an average annual return of 65.16%. Currently, Comfort Systems USA has a market capitalization of $16.87 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 5 years ago, it would be worth $1,256.85 today based on a price of $478.23 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748646010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Comfort Systems USA 5 Years Ago Would Be Worth Today

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) has outperformed the market over the past 5 years by 47.83% on an annualized basis producing an average annual return of 61.68%. Currently, IES Hldgs has a market capitalization of $5.16 billion. 
Buying $100 In IESC: If an investor had bought $100 of IESC stock 5 years ago, it would be worth $1,103.53 today based on a price of $259.66 for IESC at the time of writing.
<h3>IES Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748645112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IESC

$100 Invested In IES Hldgs 5 Years Ago Would Be Worth This Much Today

STLD

UPDATE: President Donald Trump Says He Would Be Increasing Tariffs On Steel To 50% From 25%; Tariffs To Go Into Effect Next Week

<a href="https://www.youtube.com/watch?v=xqnyP6mUI7w">https://www.youtube.com/watch?v=xqnyP6mUI7w</a>

General

President Trump Says U.S. Steel Will Be Controlled By USA; Says Steel Tariffs Go Into Effect Next Week

<a href="https://www.bloomberg.com/news/articles/2025-05-30/trump-to-raise-steel-tariffs-to-50-to-help-nippon-us-steel-deal?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-05-30/trump-to-raise-steel-tariffs-to-50-to-help-nippon-us-steel-deal?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/trump-to-raise-steel-tariffs-to-50-to-help-nippon-us-steel-deal?embedded-checkout=true</a>

'Trump to Raise Steel Tariffs to 50% to Help Nippon-US Steel Deal'- Bloomberg

In the current market session, Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) share price is at $77.89, after a 0.84% drop. Over the past month, the stock spiked by 1.38%, but over the past year, it actually fell by 3.53%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1748642422_0.png" alt="Past Year Chart" />

<h3>Principal Financial Group P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Principal Financial Group has a better P/E ratio of 16.82 than the aggregate P/E ratio of 13.53 of the Insurance industry. Ideally, one might believe that Principal Financial Group Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748642422_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Principal Financial Group

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) has outperformed the market over the past 20 years by 1.42% on an annualized basis producing an average annual return of 9.7%. Currently, Constellation Brands has a market capitalization of $31.79 billion. 
Buying $100 In STZ: If an investor had bought $100 of STZ stock 20 years ago, it would be worth $634.94 today based on a price of $178.58 for STZ at the time of writing.
<h3>Constellation Brands's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748642418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-05-30/trump-officials-set-for-talks-with-asia-leaders-on-alaska-energy?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/trump-officials-set-for-talks-with-asia-leaders-on-alaska-energy?embedded-checkout=true</a>

'Trump Officials Set for Talks With Asia Leaders on Alaska Energy'- Bloomberg

SBET

SharpLink Gaming Files For Mixed Shelf Offering; Size Not Disclosed

CELU

Celularity Receives Nasdaq Letter Regarding Form 10-Q

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) has outperformed the market over the past 15 years by 5.91% on an annualized basis producing an average annual return of 18.07%. Currently, Salesforce has a market capitalization of $253.42 billion. 
Buying $1000 In CRM: If an investor had bought $1000 of CRM stock 15 years ago, it would be worth $11,841.59 today based on a price of $265.08 for CRM at the time of writing.
<h3>Salesforce's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748640629_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

<ul>
<li>Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented</li>
<li>[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatment</li>
<li>Four of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject to confirmation.</li>
<li>Seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up</li>
<li>Perspective will hold a conference call on Monday, June 2, 2025 at 8:00 am ET &nbsp;</li>
</ul>

Biotech

CATX

Perspective Therapeutics Reveals New Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET At The 2025 ASCO Annual Meeting

Earnings

Press Releases

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Health Care

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Analyst Ratings

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Comments

NewAmsterdam Pharma Co

NewAmsterdam Pharma Co (NAMS) Opciones

NewAmsterdam Pharma Co (NASDAQ:NAMS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL